Insulet Corporation (PODD) Expected to Post Earnings of -$0.07 Per Share
Analysts forecast that Insulet Corporation (NASDAQ:PODD) will report earnings of ($0.07) per share for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have issued estimates for Insulet Corporation’s earnings, with estimates ranging from ($0.15) to ($0.01). Insulet Corporation posted earnings of ($0.16) per share in the same quarter last year, which would suggest a positive year over year growth rate of 56.3%. The business is scheduled to issue its next earnings report on Monday, February 26th.
On average, analysts expect that Insulet Corporation will report full-year earnings of ($0.42) per share for the current financial year, with EPS estimates ranging from ($0.53) to ($0.35). For the next fiscal year, analysts forecast that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.62) to $0.30. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Insulet Corporation.
Insulet Corporation (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. The company had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. Insulet Corporation had a negative net margin of 6.66% and a negative return on equity of 43.85%. Insulet Corporation’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) EPS.
PODD has been the subject of a number of analyst reports. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Insulet Corporation in a research report on Saturday, July 22nd. BidaskClub downgraded shares of Insulet Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. Cowen and Company restated an “outperform” rating and set a $63.00 price objective (up previously from $52.00) on shares of Insulet Corporation in a research report on Friday, August 4th. Northland Securities restated a “buy” rating on shares of Insulet Corporation in a research report on Friday, August 4th. Finally, Jefferies Group LLC restated a “buy” rating and set a $58.00 price objective (up previously from $48.00) on shares of Insulet Corporation in a research report on Wednesday, August 9th. Seven analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Insulet Corporation presently has a consensus rating of “Buy” and an average target price of $60.36.
Insulet Corporation (NASDAQ PODD) opened at $70.64 on Friday. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. Insulet Corporation has a 12-month low of $32.12 and a 12-month high of $72.26.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/18/insulet-corporation-podd-expected-to-post-earnings-of-0-07-per-share.html.
In other Insulet Corporation news, Director James C. Mullen acquired 2,500 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average cost of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 1.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of PODD. Principal Financial Group Inc. grew its stake in Insulet Corporation by 1.1% in the 1st quarter. Principal Financial Group Inc. now owns 8,171 shares of the medical instruments supplier’s stock valued at $352,000 after acquiring an additional 92 shares during the last quarter. Renaissance Technologies LLC grew its stake in Insulet Corporation by 17.1% in the 1st quarter. Renaissance Technologies LLC now owns 148,700 shares of the medical instruments supplier’s stock valued at $6,407,000 after acquiring an additional 21,700 shares during the last quarter. BlackRock Inc. grew its stake in Insulet Corporation by 7,285.2% in the 1st quarter. BlackRock Inc. now owns 4,194,117 shares of the medical instruments supplier’s stock valued at $180,724,000 after acquiring an additional 4,137,326 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Insulet Corporation by 11.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 244,271 shares of the medical instruments supplier’s stock valued at $10,526,000 after acquiring an additional 25,241 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Insulet Corporation by 4.5% during the 1st quarter. Bank of America Corp DE now owns 153,544 shares of the medical instruments supplier’s stock worth $6,616,000 after purchasing an additional 6,575 shares during the last quarter.
Insulet Corporation Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related stocks with our FREE daily email newsletter.